Sarepta Therapeutics, Inc.
SRPT
Positions held
Your positionsSRPT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Sarepta Therapeutics is focused on developing innovative therapies for rare diseases, positioning itself uniquely in the biotechnology sector with a strong pipeline.
- The company has a current ratio of 4.422, indicating a strong liquidity position to cover short-term liabilities.
- Despite recent challenges, Sarepta's gross margin was 62.8% in the latest quarter, showcasing its potential for profitability.
- The biotechnology industry is highly competitive, and Sarepta faces significant challenges in maintaining its market position amid evolving therapies.
- Revenue decreased by 45% compared to the prior quarter, dropping from $731M to $401M.
- Sarepta's score indicates a 'Strong Sell' with a score of -24.00, reflecting negative market sentiment and operational struggles.
Fundamentals
| Market cap | $1.92B | Enterprise value | $2.20B | Trailing P/E | — | Forward P/E | 7.55 |
| PEG | -0.09 | Price / book | 1.26 | Beta | 0.38 | Dividend yield | 0.00% |
| Revenue growth | -34.3% | Earnings growth | — | Gross margin | 19.1% | Operating margin | 13.0% |
| Profit margin | -6.9% | ROE | -9.5% | ROA | -1.1% | Debt / equity | 0.70 |
| Current ratio | 4.42 | Free cash flow | $22.14M | Analyst recommendation | hold | Mean target | $21.64 |
| 52w high | $24.68 | 52w low | $14.68 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $401M | $731M | $443M | $399M | $611M | — |
| Op margin | 13.0% | 49.0% | -92.6% | -15.7% | 18.9% | — |
| Net income | -$4.9M | $331M | -$283M | -$180M | $197M | — |
| Gross margin | 62.8% | 85.1% | 10.0% | 62.2% | 75.0% | — |
| Gross profit | $252M | $622M | $44.2M | $249M | $459M | — |
| Operating income | $52.3M | $358M | -$410M | -$62.9M | $116M | — |
- Revenue -45% vs prior quarter ($401M vs $731M).
- Gross margin 62.8% (was 85.1% prior quarter).
- Operating margin compressed to 13%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $1.2B | $933M | — |
| Op margin | -29.9% | 11.5% | -21.5% | -57.5% | — |
| Net income | -$713M | $235M | -$536M | -$703M | — |
| Gross margin | 61.8% | 83.2% | 87.9% | 85.0% | — |
| Gross profit | $1.4B | $1.6B | $1.1B | $793M | — |
| Operating income | -$658M | $218M | -$268M | -$536M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Cuts Price Target on Sarepta Therapeutics to $17 From $19, Keeps Sector Perform, Speculative Risk
2026-10-07 · Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics
2026-09-30 · Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-26 · Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn
2026-09-25 · Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
2026-09-22 · Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
2026-09-15 · Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
2026-09-08 · Novartis Stock Tanks Following Third Major Pipeline Setback
2026-09-08 · Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Price (daily)
Full chart · RSI · MACD · patterns